Medicare AdvantageCoverageMedium impact
MA07.008e, Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions
Independence Blue Cross·Orthopedics, Wound Care, PM&R (Physical Medicine & Rehab) +1 more·Medical Policy
Effective date
Jan 6, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated their policy MA07.008e regarding stem-cell therapy and platelet-rich plasma treatments for orthopedic applications and wound healing. This policy change affects coverage and reimbursement positions for these specialized treatments.
Action Required
By January 6, 2025: Billing team must review updated Medicare Advantage policy MA07.008e for stem-cell therapy and platelet-rich plasma treatments. Verify current coverage criteria and reimbursement guidelines for orthopedic applications and wound healing procedures. Update billing protocols and prior authorization requirements as specified in the full policy document.